
1. Technology overview
VidaSense is a Swiss medtech startup that describes itself as rooted in Bern, Switzerland, where its wearable is developed at the CSEM institute. A Startupticker article of April 2026 describes it as a CSEM spin-off. It targets next-generation wearable pregnancy monitoring for expectant mothers and healthcare professionals.
The product is a single ECG-based wearable that tracks maternal heart rate, uterine contractions, fetal heart rate and fetal movement using active dry-electrode technology for fetal ECG, without ultrasound gel and described as fully non-invasive. It supports remote monitoring and risk alerts that connect mothers with clinicians. The company states an acceptance rate above 80 percent and an error below 6 BPM without citing supporting data.
2. Highlighted features & specifications
- Fetal ECG: Active dry-electrode technology captures fetal ECG non-invasively.
- Multi-parameter tracking: Maternal heart rate, uterine contractions, fetal heart rate and fetal movement.
- No gel: No ultrasound gel is needed.
- Remote monitoring: Connects mothers with healthcare professionals.
- Risk alerts: Flags risks for clinician review.
- Point-of-care use: Intended for use in clinical and care settings.
3. Potential application
Labor-ward monitoring in obstetric hospitals in Vietnam. Remote follow-up of high-risk pregnancies by private maternity clinics. Clinical research on fetal monitoring.
4. Benefits
Non-invasive monitoring with dry electrodes and no ultrasound gel. A single device covers maternal and fetal heart rate, contractions and fetal movement. Remote monitoring and risk alerts connect mothers with healthcare professionals. A clinical study in labor wards assesses signal quality, accuracy and maternal comfort.
5. Market trends & opportunities
Maternity services are looking for wearable alternatives to belt-based ultrasound monitoring, with attention on remote follow-up of pregnancy. Vietnamese obstetric hospitals and private maternity networks are potential users once the device has regulatory clearance.
6. Other information
Swiss startup in Bern, developed at CSEM. Per Startupticker (16 April 2026), a clinical study at the labor wards of Inselspital Bern covers 25 patients and 75 one-hour measurements to assess signal quality, accuracy and maternal comfort. The website lists no certification or clearance; founding year and legal entity are not stated.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































